March 21, 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read MoreMarch 5, 2024
Please click here for further details of the Results Announcement.
• Read MoreMarch 4, 2024
Please click here for further details of the Launch Announcement.
• Read MoreJanuary 2, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Successful validation of LungLB® in multi-site, prospective clinical study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces the successful validation of its LungLB® test for indeterminate lung nodules from a prospective, multi-site clinical study in the clinically important small […]
• Read MoreSeptember 28, 2023
LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]
• Read MoreAugust 14, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read MoreAugust 8, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2023. Operational Highlights: Completed enrolment of the Company’s 425-participant pivotal clinical validation study in May, in line […]
• Read MoreAugust 3, 2023
3 August 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023. Investor presentation Paul Pagano, […]
• Read MoreJune 6, 2023
6 June 2023 LungLife AI, Inc. (the “Company” or “LungLife”) LungLB® study demonstrating high performance published in peer-reviewed journal LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the publication of successful performance results for the Company’s blood-based LungLB® test from a multi-site prospective study in patients with indeterminate pulmonary […]
• Read MoreMay 23, 2023
23 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Enrolment completed for pivotal validation study of LungLB® Company to work with clinical sites to ensure data quality ahead of analysis and readout LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal […]
• Read More
LungLife AI licensure/accreditation information posted here.